| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 14 | 2024 | 374 | 4.250 |
Why?
|
| Antineoplastic Agents, Immunological | 7 | 2024 | 215 | 2.390 |
Why?
|
| Antibodies, Monoclonal, Humanized | 9 | 2025 | 977 | 2.240 |
Why?
|
| Neoplasms | 17 | 2025 | 3117 | 2.060 |
Why?
|
| Programmed Cell Death 1 Receptor | 6 | 2024 | 183 | 1.920 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 4 | 2024 | 22 | 1.800 |
Why?
|
| Immunotherapy | 14 | 2025 | 725 | 1.740 |
Why?
|
| Tumor Microenvironment | 12 | 2025 | 520 | 1.680 |
Why?
|
| Urologic Neoplasms | 5 | 2025 | 75 | 1.490 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2025 | 2556 | 1.310 |
Why?
|
| Membrane Proteins | 3 | 2025 | 1240 | 1.230 |
Why?
|
| Kidney Neoplasms | 5 | 2024 | 530 | 1.230 |
Why?
|
| Carcinoma, Transitional Cell | 5 | 2024 | 154 | 1.220 |
Why?
|
| B7-H1 Antigen | 6 | 2024 | 286 | 1.070 |
Why?
|
| Cisplatin | 3 | 2024 | 602 | 0.970 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2024 | 343 | 0.950 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2016 | 153 | 0.950 |
Why?
|
| Interleukin-7 | 1 | 2025 | 47 | 0.930 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2021 | 419 | 0.710 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2021 | 89 | 0.700 |
Why?
|
| Urothelium | 1 | 2020 | 65 | 0.680 |
Why?
|
| Biomarkers, Tumor | 6 | 2024 | 1576 | 0.680 |
Why?
|
| HLA Antigens | 1 | 2021 | 227 | 0.660 |
Why?
|
| Immunity | 2 | 2019 | 149 | 0.640 |
Why?
|
| Venae Cavae | 1 | 2019 | 12 | 0.630 |
Why?
|
| Humans | 49 | 2025 | 92337 | 0.610 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 4 | 2024 | 149 | 0.610 |
Why?
|
| Antigens, Neoplasm | 2 | 2020 | 345 | 0.600 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 291 | 0.600 |
Why?
|
| Biopsy | 3 | 2016 | 1194 | 0.580 |
Why?
|
| Ascites | 1 | 2018 | 57 | 0.580 |
Why?
|
| Lymphoma | 3 | 2025 | 267 | 0.560 |
Why?
|
| Sulfonamides | 2 | 2016 | 328 | 0.550 |
Why?
|
| CTLA-4 Antigen | 1 | 2017 | 141 | 0.530 |
Why?
|
| T-Lymphocytes | 3 | 2021 | 1277 | 0.520 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 253 | 0.510 |
Why?
|
| Carcinoma | 1 | 2019 | 438 | 0.510 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2024 | 333 | 0.460 |
Why?
|
| Melanoma | 3 | 2025 | 482 | 0.450 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 296 | 0.440 |
Why?
|
| Precision Medicine | 1 | 2018 | 425 | 0.430 |
Why?
|
| Pyrimidines | 1 | 2016 | 378 | 0.430 |
Why?
|
| Silicic Acid | 1 | 2013 | 1 | 0.420 |
Why?
|
| Aluminum Hydroxide | 1 | 2013 | 3 | 0.420 |
Why?
|
| Antacids | 1 | 2013 | 4 | 0.420 |
Why?
|
| Magnesium Oxide | 1 | 2013 | 4 | 0.420 |
Why?
|
| Sodium Bicarbonate | 1 | 2013 | 9 | 0.420 |
Why?
|
| Alginates | 1 | 2013 | 17 | 0.420 |
Why?
|
| Postprandial Period | 1 | 2013 | 47 | 0.410 |
Why?
|
| Receptors, Glucocorticoid | 2 | 2024 | 141 | 0.410 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 619 | 0.400 |
Why?
|
| Aged, 80 and over | 8 | 2025 | 6916 | 0.400 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2011 | 3 | 0.370 |
Why?
|
| Actinomyces | 1 | 2011 | 5 | 0.370 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2011 | 8 | 0.370 |
Why?
|
| Actinomycosis | 1 | 2011 | 12 | 0.370 |
Why?
|
| Middle Aged | 15 | 2025 | 27030 | 0.370 |
Why?
|
| Aged | 15 | 2025 | 19943 | 0.360 |
Why?
|
| Gastroesophageal Reflux | 1 | 2013 | 126 | 0.360 |
Why?
|
| Treatment Outcome | 9 | 2025 | 8740 | 0.350 |
Why?
|
| Germ-Line Mutation | 2 | 2025 | 358 | 0.340 |
Why?
|
| Neoplasms, Second Primary | 2 | 2023 | 245 | 0.330 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 1138 | 0.330 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2023 | 318 | 0.320 |
Why?
|
| Female | 18 | 2025 | 47893 | 0.310 |
Why?
|
| beta Catenin | 3 | 2021 | 266 | 0.290 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 3509 | 0.290 |
Why?
|
| Breast Neoplasms | 3 | 2022 | 3053 | 0.280 |
Why?
|
| Lymph Nodes | 1 | 2011 | 552 | 0.280 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2024 | 624 | 0.270 |
Why?
|
| Lung Neoplasms | 2 | 2019 | 2394 | 0.270 |
Why?
|
| Indazoles | 2 | 2016 | 60 | 0.260 |
Why?
|
| Lymphocyte Activation | 2 | 2021 | 786 | 0.250 |
Why?
|
| Neoplasm Invasiveness | 2 | 2024 | 569 | 0.250 |
Why?
|
| Protein Kinase C-delta | 1 | 2025 | 29 | 0.240 |
Why?
|
| Male | 14 | 2025 | 43925 | 0.240 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2024 | 19 | 0.230 |
Why?
|
| Organosilicon Compounds | 1 | 2004 | 5 | 0.230 |
Why?
|
| Myeloid Cells | 1 | 2025 | 106 | 0.230 |
Why?
|
| Silver | 1 | 2004 | 16 | 0.230 |
Why?
|
| Alkynes | 1 | 2004 | 19 | 0.230 |
Why?
|
| Phenylthiohydantoin | 1 | 2024 | 47 | 0.220 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2024 | 45 | 0.220 |
Why?
|
| Watchful Waiting | 1 | 2024 | 69 | 0.220 |
Why?
|
| Nitriles | 1 | 2024 | 158 | 0.210 |
Why?
|
| Signal Transduction | 4 | 2024 | 3508 | 0.210 |
Why?
|
| Benzamides | 1 | 2024 | 239 | 0.210 |
Why?
|
| Wnt Signaling Pathway | 2 | 2021 | 103 | 0.200 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 1150 | 0.200 |
Why?
|
| Recombinant Proteins | 1 | 2025 | 1016 | 0.200 |
Why?
|
| Disease Progression | 2 | 2018 | 1503 | 0.200 |
Why?
|
| Capecitabine | 2 | 2024 | 92 | 0.200 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2024 | 109 | 0.200 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 1477 | 0.200 |
Why?
|
| Maytansine | 1 | 2022 | 12 | 0.200 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2024 | 177 | 0.190 |
Why?
|
| Urinary Bladder | 1 | 2024 | 250 | 0.190 |
Why?
|
| Adult | 9 | 2025 | 27532 | 0.180 |
Why?
|
| Immunoconjugates | 1 | 2022 | 119 | 0.180 |
Why?
|
| Neoplasm Metastasis | 3 | 2024 | 1071 | 0.180 |
Why?
|
| Phenylurea Compounds | 1 | 2021 | 97 | 0.180 |
Why?
|
| Quinolines | 1 | 2021 | 88 | 0.180 |
Why?
|
| Cellular Reprogramming | 1 | 2021 | 45 | 0.180 |
Why?
|
| Repressor Proteins | 1 | 2024 | 434 | 0.170 |
Why?
|
| Dendritic Cells | 1 | 2024 | 455 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 1399 | 0.170 |
Why?
|
| Immunomodulation | 2 | 2018 | 62 | 0.160 |
Why?
|
| Animals | 9 | 2025 | 28003 | 0.160 |
Why?
|
| Immunity, Innate | 1 | 2023 | 438 | 0.160 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 277 | 0.160 |
Why?
|
| Mutation | 4 | 2024 | 4204 | 0.160 |
Why?
|
| Prognosis | 3 | 2024 | 3872 | 0.150 |
Why?
|
| Neoadjuvant Therapy | 2 | 2019 | 400 | 0.150 |
Why?
|
| RNA, Messenger | 1 | 2024 | 2037 | 0.150 |
Why?
|
| Microbiota | 1 | 2023 | 412 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 1310 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 291 | 0.150 |
Why?
|
| Cell Proliferation | 2 | 2021 | 1720 | 0.140 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2018 | 60 | 0.140 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 100 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 236 | 0.140 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2016 | 1 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 598 | 0.140 |
Why?
|
| Ipilimumab | 1 | 2017 | 61 | 0.130 |
Why?
|
| Therapies, Investigational | 1 | 2016 | 17 | 0.130 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 556 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 538 | 0.130 |
Why?
|
| Tumor Escape | 1 | 2016 | 52 | 0.130 |
Why?
|
| Antigen-Presenting Cells | 1 | 2016 | 142 | 0.130 |
Why?
|
| Cell Line, Tumor | 4 | 2025 | 2669 | 0.130 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 318 | 0.130 |
Why?
|
| PPAR gamma | 1 | 2016 | 74 | 0.120 |
Why?
|
| Patient Selection | 1 | 2019 | 689 | 0.120 |
Why?
|
| Adjuvants, Immunologic | 1 | 2016 | 169 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 276 | 0.120 |
Why?
|
| Cluster Analysis | 1 | 2016 | 376 | 0.120 |
Why?
|
| Recurrence | 1 | 2018 | 1180 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2016 | 673 | 0.120 |
Why?
|
| Receptors, Estrogen | 1 | 2016 | 401 | 0.120 |
Why?
|
| Central Venous Catheters | 1 | 2014 | 21 | 0.110 |
Why?
|
| Combined Modality Therapy | 3 | 2024 | 1733 | 0.110 |
Why?
|
| Crohn Disease | 1 | 2021 | 772 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2021 | 2978 | 0.110 |
Why?
|
| Awareness | 1 | 2014 | 89 | 0.110 |
Why?
|
| Colitis, Ulcerative | 1 | 2021 | 775 | 0.110 |
Why?
|
| Medical Staff, Hospital | 1 | 2014 | 109 | 0.110 |
Why?
|
| Neoplasm Staging | 3 | 2024 | 2035 | 0.110 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 315 | 0.110 |
Why?
|
| Esophageal pH Monitoring | 1 | 2013 | 12 | 0.110 |
Why?
|
| Manometry | 1 | 2013 | 44 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 547 | 0.100 |
Why?
|
| Mice | 6 | 2025 | 12110 | 0.100 |
Why?
|
| Drug Combinations | 1 | 2013 | 206 | 0.100 |
Why?
|
| Electric Impedance | 1 | 2013 | 110 | 0.100 |
Why?
|
| Hospitalization | 1 | 2018 | 927 | 0.100 |
Why?
|
| Cross-Over Studies | 1 | 2013 | 390 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 2680 | 0.100 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2013 | 501 | 0.100 |
Why?
|
| Contrast Media | 1 | 2016 | 1076 | 0.090 |
Why?
|
| Cystectomy | 2 | 2024 | 114 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2022 | 2368 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 354 | 0.090 |
Why?
|
| Endothelium, Vascular | 1 | 2012 | 437 | 0.080 |
Why?
|
| Databases, Genetic | 2 | 2021 | 274 | 0.080 |
Why?
|
| Double-Blind Method | 1 | 2013 | 1756 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2014 | 806 | 0.080 |
Why?
|
| Immunohistochemistry | 2 | 2024 | 1807 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2024 | 866 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 1592 | 0.070 |
Why?
|
| Inflammation | 1 | 2012 | 1025 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2024 | 3360 | 0.060 |
Why?
|
| Injections, Subcutaneous | 1 | 2025 | 128 | 0.060 |
Why?
|
| Intention to Treat Analysis | 1 | 2024 | 75 | 0.060 |
Why?
|
| Cyclization | 1 | 2004 | 11 | 0.060 |
Why?
|
| 4-1BB Ligand | 1 | 2024 | 3 | 0.060 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2024 | 20 | 0.060 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2024 | 17 | 0.060 |
Why?
|
| Phenotype | 2 | 2021 | 2498 | 0.060 |
Why?
|
| Catalysis | 1 | 2004 | 210 | 0.050 |
Why?
|
| Perforin | 1 | 2023 | 55 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2025 | 351 | 0.050 |
Why?
|
| Receptors, Androgen | 1 | 2024 | 120 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2004 | 307 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 2448 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2024 | 485 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2021 | 2902 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2024 | 1181 | 0.050 |
Why?
|
| Retinoblastoma-Like Protein p107 | 1 | 2021 | 2 | 0.050 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2021 | 19 | 0.050 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2021 | 23 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2022 | 268 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2023 | 497 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 80 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2020 | 66 | 0.040 |
Why?
|
| Europe | 1 | 2021 | 328 | 0.040 |
Why?
|
| Interferons | 1 | 2021 | 125 | 0.040 |
Why?
|
| Wnt Proteins | 1 | 2021 | 130 | 0.040 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2021 | 124 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2025 | 2087 | 0.040 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2019 | 28 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2021 | 177 | 0.040 |
Why?
|
| Genes, BRCA1 | 1 | 2021 | 192 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2019 | 42 | 0.040 |
Why?
|
| Patient Advocacy | 1 | 2019 | 54 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2019 | 91 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2019 | 120 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 225 | 0.040 |
Why?
|
| Adoptive Transfer | 1 | 2018 | 173 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 1398 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 1589 | 0.030 |
Why?
|
| Cytokines | 1 | 2021 | 843 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2025 | 2447 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 763 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1902 | 0.030 |
Why?
|
| Patient Safety | 1 | 2018 | 221 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2019 | 601 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2019 | 393 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2014 | 22 | 0.030 |
Why?
|
| Personnel, Hospital | 1 | 2014 | 30 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 1927 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 1723 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2012 | 70 | 0.020 |
Why?
|
| Time Factors | 1 | 2021 | 5430 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 6624 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 400 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 1850 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 2394 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3775 | 0.020 |
Why?
|
| Inpatients | 1 | 2014 | 331 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2014 | 429 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 698 | 0.020 |
Why?
|
| Glioma | 1 | 2012 | 303 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 996 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2012 | 475 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 1774 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 709 | 0.020 |
Why?
|
| United States | 1 | 2021 | 7348 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2012 | 583 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2014 | 1081 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2018 | 9703 | 0.010 |
Why?
|